Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Gagan Singh Added: 4 hours ago
EuroPCR25 - Two-year data confirms sustained benefits of TriClip for severe tricuspid regurgitation.We are joined by Dr Gagan Singh (UC Davis Medical Center, Sacramento, CA, US) to discuss key findings from the TRILUMINATE pivotal trial. This randomised controlled trial compared the TriClip device against medical therapy in symptomatic patients with severe tricuspid regurgitation (TR) who are at… View more
Author(s): Sacharias Von Koch Added: 2 months ago
CRT 25 - Two-year outcomes of the Prevail paclitaxel-coated balloon show no difference in clinical outcomes compared to other drug-coated balloons (DCBs), suggesting the Prevail DCB is as effective and safe as other contemporary DCB's in a real-world setting. The Prevail DCB was also associated with lower rates of myocardial infarction in the sub-group analysis of patients who also underwent… View more
Author(s): Jeffrey W Moses Added: 2 months ago
CRT 25 - Safety and effectiveness outcomes of the Agent drug-coated balloon (DCB) for the treatment of in-stent restenosis show a major reduction in target lesion failure, including cardiac death, myocardial infarction and target lesion revascularization, compared to balloon angioplasty. The Agent DCB also caused a significant reduction in all target lesion events in comparison with the control… View more
Author(s): David Erlinge Added: 8 months ago
One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024. He highlights how the novel design and… View more
Author(s): Michael J Reardon Added: 1 month ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more
Author(s): Firas Zahr Added: 6 months ago
TCT Conference 24 - Two-year outcomes of CLASP IID shows that the Edwards PASCAL system was noninferior to the Abbott Mitraclip system in transcatheter mitral valve repair for mitral regurgitation.Dr Firas Zahr (Oregon Health and Science University, US) joins us onsite at TCT Conference to discuss the outcomes from the CLASP IID 2 Year RCT and Registry (NCT02371512; Edwards Lifesciences).CLASP… View more
Author(s): Raj Makkar Added: 1 year ago
In this insightful interview, investigator, Prof Raj R Makkar(Cedars-Sinai Heart Institute, US) joins us to discuss the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves. Prof Makkar and his team used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to address a series of questions regarding the safety… View more
Author(s): David Power Added: 3 months ago
Outcomes investigating the Absorb bioresorbable vascular scaffold (BVS) in patients undergoing percutaneous coronary intervention showed more adverse ischaemic events through 5 years compared with cobalt-chromium everolimus-eluting stents. However, the period of excess risk ended at 3 years.In this short interview, Dr David Power (Mount Sinai Hospital, New York, US) discusses the final report… View more